

FIG. 1A



FIG. 1B



FIG. 2

Leu Glu Arg Gly Arg Asp Tyr Glu Lys Asn Lys Val Cys Lys Glu Phe Ser His Leu Gly
Lys Glu Asp phe Thr Ser Leu Ser Leu Val Leu Tyr Ser Arg Lys Phe Pro Ser Gly Thr
Phe Glu Gln Val Ser Gln Leu Val Lys Glu Val Val Ser Leu Thr Glu Ala Cys Cys Ala
Glu Gly Ala Asp Pro Asp Cys Tyr Asp Thr Arg Thr Ser Ala Leu Ser Ala Lys Ser Cys
Glu Ser Asn Ser Pro Phe Pro Val His Pro Gly Thr Ala Glu Cys Cys Thr Lys Glu Gly
Leu Glu Arg Lys Leu Cys Met Ala Ala Leu Lys His Gln Pro Gln Glu Phe Pro Thr Tyr
Val Glu Pro Thr Asn Asp Glu Ile Cys Glu Ala Phe Arg Lys Asp Pro Lys GLu Tyr Ala
Asn Gln Phe Met Trp Glu Tyr Ser Thr Asn Tyr Glu Gln Ala Pro Leu Ser Leu Leu Val
Ser Tyr Thr Lys Ser Tyr Leu Ser Met Val Gly Ser Cys Cys Thr Ser Ala Ser Pro Thr
Val Cys Phe Leu Lys Glu Arg Leu Gln Leu Lys His Leu Ser Leu Leu Thr Thr Leu Ser
Asn Arg Val Cys Ser Gln Tyr Ala Ala Tyr Gly Glu Lys Lys Ser Arg Leu Ser Asn Leu
Ile Lys Leu Ala Gln Lys Val Pro Thr Ala Asp Leu Glu Asp Val Leu Pro Leu Ala Glu
Asp Ile Thr Asn Ile Leu Ser Lys Cys Cys Glu Ser Ala Ser Glu Asp Cys Met Ala Lys
Glu Leu Pro Glu His Thr Val Lys Leu Cys Asp Asn Leu Ser Thr Lys Asn Ser Lys Phe
Glu Asp Cys Cys Gln Glu Lys Thr Ala Met Asp Val Phe Val Cys Thr Tyr Phe Met Pro
Ala Ala Gln Leu Pro Glu Leu Pro Asp Val Arg Leu Pro Thr Asn Lys Asp Val Cys Asp
Pro Gly Asn Thr Lys Val Met Asp Lys Tyr Thr Phe Glu Leu Ser Arg Arg Thr His Leu
Pro Glu Val Phe Leu Ser Lys Val Leu Glu Pro Thr Leu Lys Ser Leu Gly Glu Cys Cys
Asp Val Glu Asp Ser Thr Thr Cys phe Asn Ala Lys Gly Pro Leu Leu Lys Lys Glu Leu
Ser Ser Phe Ile Asp Lys Gly Gln Glu Leu Cys Ala Asp Tyr Ser Glu Asn Thr Phe Thr
Glu Tyr Lys Lys Lys Leu Ala GlU Arg Leu Lys Ala Lys Leu Pro Glu Ala Thr Pro Thr
Glu Leu Ala Lys Leu Val Asn Lys Arg Ser Asp Phe Ala Ser Asn Cys Cys Ser Ile Asn
Ser Pro Pro Leu Tyr Cys Asp Ser Glu Ile Asp Ala Glu Leu Lys Asn Ile Leu

458

FIG. 3



A. Ge cDNA

B. Final Construct

FIG. 4

```
                                     10                                      20
Leu Glu Arg Gly Pro Leu Leu  Lys Lys Glu Leu Ser Ser Phe Ile Asp Lys Gly Gln Glu
                                     30                                      40
Leu Cys Ala Asp Tyr Ser Glu  Asn Thr Phe Thr Glu Tyr Lys Lys Lys Leu Ala Glu Arg
                                     50                                      60
Leu Lys Ala Lys Leu Pro Glu  Ala Thr Pro Thr Glu Leu Ala Lys Leu Val Asn Lys Arg
                                     70                                      80
Ser Asp Phe Ala Ser Asn Cys  Cys Ser Ile Asn Ser Pro Pro Leu Tyr Cys Asp Ser Glu
                                 89
Ile Asp Ala Glu Leu Lys Asn  Ile Leu
```

FIG. 5

FIG. 6



pPbac ...GCTAGCCATC.ATG.GTG... ...GAG.AAC.CCG.GGA...
start

									10										20
Ile	Ile	Pro	Val	Glu	Glu	Glu	Asn	Pro	Pro	Leu	Leu	Lys	Lys	Glu	Leu	Ser	Ser	Phe	Ile
									30										40
Asp	Lys	Gly	Gln	Glu	Leu	Cys	Ala	Asp	Tyr	Ser	Glu	Asn	Thr	Phe	Thr	Glu	Tyr	Lys	Lys
									50										60
Lys	Leu	Ala	Glu	Arg	Leu	Lys	Ala	Lys	Leu	Pro	Glu	Ala	Thr	Pro	Thr	Glu	Leu	Ala	Lys
									70										80
Leu	Val	Asn	Lys	Arg	Ser	Asp	Phe	Ala	Ser	Asn	Cys	Cys	Ser	Ile	Asn	Ser	Pro	Pro	Leu
									90				94						
Tyr	Cys	Asp	Ser	Glu	Ile	Asp	Ala	Glu	Leu	Lys	Asn	Ile	Leu						

FIG. 7

FIG. 8A


PROSTATE CANCER
GcMAF THERAPY
PATIENT 52
PATIENT 75
PATIENT 148
PATIENT 72
PATIENT 69
PATIENT 39
PATIENT 11
PATIENT 71
PATIENT 215
PATIENT 73
PATIENT 134
α-N-ACETYLGALACTOSAMINIDASE
(nmoles/mg/min)
HEALTHY
HUMAN
0
1
2
3
4
5
6
0
2
4
6
8
10
12
14
16
18
20
22
24
WEEKS

FIG. 8B


BREAST CANCER
GcMAF THERAPY
PATIENT 1-23
PATIENT 2-128
PATIENT 3-60
PATIENT 4-44
PATIENT 5-30
PATIENT 6-151
PATIENT 7-186
PATIENT 8-29
PATIENT 9-123
PATIENT 10-115
PATIENT 11-193
PATIENT 12-176
α-N-ACETYLGALACTOSAMINIDASE (nmoles/mg/min)
HEALTHY HUMAN
WEEKS
0
1
2
3
4
5
6
7
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32

FIG. 8C


COLON CANCER
GcMAF THERAPY
PATIENT 8
PATIENT 4
PATIENT 5
PATIENT 3
PATIENT 15
PATIENT 16
α-N-ACETYLGALACTOSAMINIDASE
(nmoles/mg/min)
HEALTHY
HUMAN
0
1
2
3
4
5
6
7
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48
WEEKS

FIG. 8D


Leukemia
GcMAF THERAPY
#32 CLL
#34 CLL
#42 CLL
#47 CLL
#48 CLL
#49 CLL
#125 CLL
α-N-ACETYLGALACTOSAMINIDASE
(nmoles/mg/min)
HEALTHY
HUMAN
0
1
2
3
4
5
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
WEEKS